CM
RXRX icon

Caption Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Caption Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-420,801
Closed -$2.21M – 1992
2025
Q2 		$2.13M Buy
+420,801
New +$2.07M 0.02% 694
2025
Q1 		– Sell
-102,900
Closed -$750K – 1970
2024
Q4 		$696K Buy
+102,900
New +$692K 0.01% 1005

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's RXRX Position: Q3 2025 in Review

Caption Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 420,801 shares — an estimated $2.21M sold.

Caption Management first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $2.13M in Q2 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Caption Management reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 420,801 Recursion Pharmaceuticals shares in Q3 2025, an estimated $2.21M.
  • Caption Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Caption Management's Recursion Pharmaceuticals position peaked at $2.13M in Q2 2025.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.